Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
MAFLD
1 other identifier
observational
2,000
1 country
1
Brief Summary
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 6, 2022
CompletedStudy Start
First participant enrolled
June 10, 2022
CompletedFirst Posted
Study publicly available on registry
June 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedJune 16, 2022
May 1, 2022
7 months
June 6, 2022
June 13, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To investigate the prevalence of MAFLD among adults at multiple health examination centers across China.
MAFLD means metabolic dysfunction-associated fatty liver disease
through study completion, an average of 1 year
Secondary Outcomes (4)
To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²).
through study completion, an average of 1 year
To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²)
through study completion, an average of 1 year
To assess the prevalence of type 2 diabetes among patients with MAFLD.
through study completion, an average of 1 year
To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD.
through study completion, an average of 1 year
Study Arms (1)
Single Group Assignment
Adults with health check-ups at multiple health examination centers across China
Interventions
Fibrotouch will be performed showing the stiffness and fat content of liver
Eligibility Criteria
adults with health check-ups at multiple health examination centers across China.
You may qualify if:
- Aged between 18 and 75, both sex;
- Able to sign informed consent.
You may not qualify if:
- Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bejing Tsinghua Chang Gung Hospital
Beijing, Bejing, 100034, China
Related Publications (2)
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
PMID: 26707365BACKGROUNDEslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Jarvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
PMID: 32278004BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 6, 2022
First Posted
June 16, 2022
Study Start
June 10, 2022
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
June 16, 2022
Record last verified: 2022-05